Navigation Links
Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
Date:1/10/2012

BETHLEHEM, Pa., Jan. 10, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.  The issued patents are as follows:

  • Busulfan Immunoassay: U.S. Patent No. 7,893,220
  • Stabilized Standards for Busulfan Immunoassay: U.S. Patent No. 8,039,220
  • Doxorubicin Immunoassay: U.S. Patent No. 8,053,205
  • Imatinib Immunoassay: U.S. Patent No. 8,076,097
  • Doxorubicin Immunoassay: U.S. Patent No. 8,084,586
  • Resperidone Immunoassay: U.S. Patent No. 8,088,594

"The issuance of these patents in the U.S. positions Saladax as the leader in chemotherapy dose management and we believe that Saladax has been issued more patents in the therapeutic dose management (TDM) space than any other diagnostic company," said Salvatore J. Salamone, founder and CSO of Saladax.  "Of particular note, our patent for Resperidone marks a significant milestone for Saladax as this is our first patent in the CNS field."

About My5-FU™

Saladax's first commercially available test for innovative dose management, My5-FU, measures levels of 5-fluorouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays for paclitaxel and docetaxel.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Announces European Commercialization Team
2. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
3. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
4. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
5. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
6. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
7. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
8. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
9. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
11. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... at a Marketing Roundtable on March 22 in Philadelphia. The event was offered ... , The Marketing Roundtable featured breakout groups and interaction with speakers ...
(Date:3/28/2017)... , March 28, 2017 Volition America, Inc., ... today announced the engagement of Deborah Vollmer Dahlke , ... strategic consultant. Dr. Vollmer Dahlke,s role will be ... in the State of Texas and ... Vollmer Dahlke has significant experience over the past ...
(Date:3/28/2017)... ... 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, Inc. ... LabKey Biologics . Built in collaboration with Just and designed with input ... drug research teams tools for biological entity registration, assay data integration, and workflow ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
Breaking Biology News(10 mins):